Fierce Biotech38m
Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Rolling Out51m
The spice trick that helps burn belly fat overnight
This spice may boost overnight fat burning and target belly fat by optimizing metabolism while you sleep. Discover how it ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...
Guernsey Press58m
Michael Mosley’s son writes book on weight-loss drugs continuing father’s work
The late TV doctor’s wife Dr Clare Bailey Mosley is also bringing out a cookbook titled Eating Together: A Recipe For ...
STAT49m
Pharmalittle: We’re reading about HHS buyout offers, a Novo obesity trial, and more
Most HHS workers were emailed an offer to leave their job for as much as $25,000 as part of President Trump’s government cuts ...